Literature DB >> 30739214

Guidelines for Treatment and Monitoring of Adult Survivors of Pediatric Brain Tumors.

Anna J Janss1, Claire Mazewski2, Briana Patterson3.   

Abstract

OPINION STATEMENT: Pathologies of pediatric brain tumors are more varied than those diagnosed in adults and survival outcomes more optimistic. Therapies for pediatric brain tumors are also diverse and treatment options are expanding. The growing number of adult survivors of childhood brain tumors is quite diverse. Medical management of these adults requires understanding the tumor diagnosis and location, the modalities used to treat the tumor, the age of the survivor at the time of diagnosis and treatment, any complications of treatment, and, most importantly, the baseline medical condition and neurological function of each adult survivor. A network of medical, neurological, and mental health providers is critical in the care of a child with a brain tumor. A comparable network should be available to survivors of these tumors since they may transition to adulthood with medical and neurological deficits and can acquire additional late effects of treatments as they age. Optimally, each survivor will have an individualized survivor health plan (SHP) that concisely summarizes the tumor, treatments, potential late effects, and screening that may identify evolving late effects before they impact mental, social or physical functioning. This plan helps patients, families, and the medical team advocate for surveillance aiming to optimize the survivor's quality of life. Failure to support the health and function of these heroic cancer survivors renders the medical advances, the courage, and the struggle that permitted survival meaningless.

Entities:  

Keywords:  Frailty; Hypothalamic syndromes; Long-term cancer survivor guidelines; Pediatric brain tumor survivors; Radiation-induced cognitive impairment; Treatment-induced secondary malignancies

Mesh:

Year:  2019        PMID: 30739214     DOI: 10.1007/s11864-019-0602-0

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  54 in total

1.  Specialized survivor clinic attendance is associated with decreased rates of emergency department visits in adult survivors of childhood cancer.

Authors:  Rinku Sutradhar; Mohammad Agha; Jason D Pole; Mark Greenberg; Astrid Guttmann; David Hodgson; Paul C Nathan
Journal:  Cancer       Date:  2015-09-25       Impact factor: 6.860

2.  Long-term effects of transient cerebellar mutism after cerebellar astrocytoma or medulloblastoma tumor resection in childhood.

Authors:  Joelene F Huber; Kim Bradley; Brenda J Spiegler; Maureen Dennis
Journal:  Childs Nerv Syst       Date:  2005-09-10       Impact factor: 1.475

3.  The spectrum of neurobehavioural deficits in the Posterior Fossa Syndrome in children after cerebellar tumour surgery.

Authors:  Coriene E Catsman-Berrevoets; Femke K Aarsen
Journal:  Cortex       Date:  2009-10-29       Impact factor: 4.027

4.  Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study.

Authors:  Eva Steliarova-Foucher; Charles Stiller; Peter Kaatsch; Franco Berrino; Jan-Willem Coebergh; Brigitte Lacour; Max Parkin
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

5.  Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma.

Authors:  Mariam P Korah; Natia Esiashvili; Claire M Mazewski; Roger J Hudgins; Mourad Tighiouart; Anna J Janss; Frederick P Schwaibold; Ian R Crocker; Walter J Curran; Robert B Marcus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-19       Impact factor: 7.038

Review 6.  Late neurocognitive sequelae in survivors of brain tumours in childhood.

Authors:  Raymond K Mulhern; Thomas E Merchant; Amar Gajjar; Wilburn E Reddick; Larry E Kun
Journal:  Lancet Oncol       Date:  2004-07       Impact factor: 41.316

7.  Randomized Trial of the Impact of Empowering Childhood Cancer Survivors With Survivorship Care Plans.

Authors:  Nina S Kadan-Lottick; Wilhelmenia L Ross; Hannah-Rose Mitchell; Jaime Rotatori; Cary P Gross; Xiaomei Ma
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

Review 8.  Optic nerve glioma: an update.

Authors:  Akshay Gopinathan Nair; Rima S Pathak; Veena R Iyer; Rashmin A Gandhi
Journal:  Int Ophthalmol       Date:  2014-04-16       Impact factor: 2.031

9.  Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies.

Authors:  Gregory T Armstrong; Neelam Jain; Wei Liu; Thomas E Merchant; Marilyn Stovall; Deo Kumar Srivastava; James G Gurney; Roger J Packer; Leslie L Robison; Kevin R Krull
Journal:  Neuro Oncol       Date:  2010-08-17       Impact factor: 13.029

Review 10.  Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity.

Authors:  Hermann L Müller
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

View more
  4 in total

1.  Risk of Second Primary Neoplasms of the Central Nervous System.

Authors:  Elisa K Liu; Cheongeun Oh; Douglas Kondziolka; Erik P Sulman
Journal:  Adv Radiat Oncol       Date:  2022-04-18

Review 2.  Transitional Care in Pediatric Brain Tumor Patients: A Systematic Literature Review.

Authors:  Florian Ebel; Ladina Greuter; Raphael Guzman; Jehuda Soleman
Journal:  Children (Basel)       Date:  2022-04-02

3.  Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma.

Authors:  Makoto Ohno; Yasuji Miyakita; Masamichi Takahashi; Shunsuke Yanagisawa; Yukie Tamura; Daisuke Kawauchi; Miyu Kikuchi; Hiroshi Igaki; Akihiko Yoshida; Kaishi Satomi; Yuko Matsushita; Koichi Ichimura; Yoshitaka Narita
Journal:  Radiat Oncol       Date:  2022-05-03       Impact factor: 4.309

Review 4.  Interdisciplinary Approaches to Survivorship with a Focus on the Low-grade and Benign Brain Tumor Populations.

Authors:  Stacey L Worrell; Michelle L Kirschner; Rhonna S Shatz; Soma Sengupta; Melissa G Erickson
Journal:  Curr Oncol Rep       Date:  2021-01-20       Impact factor: 5.075

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.